NCT06568094

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Phase IRecruitingJiangsu HengRui Medicine Co., Ltd.

Prostate Cancer
Prostatic Neoplasms

See how this trial matches your record

Connect MyChart to see which criteria your record clearly satisfies, which need a clinician’s review, and which appear to disqualify you. Your data is read in this browser tab and never sent to our servers.

Summary

The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.

Interventions

DRUGHRS-5041 tablets
DRUGAbiraterone Acetate tablets（II）
DRUGPrednisone Acetate tablets
DRUGDocetaxel Injection
DRUGHRS-1167 tablets
DRUGSHR2554 tablets
DRUGHRS-6208 capsules
DRUGDarolutamide Tablets

Eligibility

Inclusion criteria

Must be at least 18 years old
Must be 80 years old or younger
Must be male

Locations

China

The Second Affiliated Hospital of Harbin Medical University
Harbin, China
Xuedong Li
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, China
Wei Xue